Table a5 Sensitivity analyses for primary and secondary outcomes of mould-active vs fluconazole prophylaxis
Analyses for all included studies | Sensitivity analysis-studies of itraconazole capsules removed ( Annaloro et al, 1995; Huijgens et al, 1999b) | |||
|---|---|---|---|---|
Outcome | Risk ratio* (95% CI) | P -value | Risk ratio* (95% CI) | P- value |
Proven or probable IFI | 0.71 (0.52, 0.98) | 0.03 | 0.68 (0.49, 0.94) | 0.02 |
Invasive aspergillosis | 0.53 (0.37, 0.75) | 0.0004 | 0.50 (0.35, 0.71) | 0.0001 |
Adverse events requiring antifungal treatment discontinuation or modification | 1.95 (1.24, 3.07) | 0.004 | 1.95 (1.24, 3.07) | 0.004 |
IFI-related mortality | 0.67 (0.47, 0.96) | 0.03 | 0.62 (0.43, 0.90) | 0.01 |
Invasive aspergillosis-related mortality | 0.62 (0.23, 1.71) | 0.36 | 0.41 (0.12, 1.39) | 0.15 |
Overall mortality | 1.00 (0.88, 1.13) | 0.96 | 0.99 (0.87, 1.13) | 0.85 |
Sensitivity analysis-studies of Itraconazole 200 mg per day removed ( Choi et al, 2005; Ito et al, 2007b; Ota et al, 2010) | ||||
Proven or probable IFI | 0.71 (0.52, 0.98) | 0.03 | 0.72 (0.53, 0.99) | 0.05 |
Invasive aspergillosis | 0.53 (0.37, 0.75) | 0.0004 | 0.54 (0.38, 0.76) | 0.0005 |
Adverse events requiring antifungal treatment discontinuation or modification | 1.95 (1.24, 3.07) | 0.004 | 1.85 (1.13, 3.03) | 0.01 |
IFI-related mortality | 0.67 (0.47, 0.96) | 0.03 | 0.66 (0.46, 0.95) | 0.02 |
Invasive aspergillosis-related mortality | 0.62 (0.23, 1.71) | 0.36 | 0.62 (0.23, 1.71) | 0.36 |
Overall mortality | 1.00 (0.88, 1.13) | 0.96 | 1.00 (0.88, 1.14) | 0.98 |
